NEW YORK (GenomeWeb News) – Manhattan Labs will market CombiMatrix's chromosomal microarray testing services to customers in the New York City metropolitan area, the firms said today.
Manhattan Labs CEO Ken Cerney said in a statement that the independent clinical laboratory opted to offer the test as part of a new focus on miscarriage management, and added that his firm "believes in the growing importance and clinical advantages microarray testing provides for appropriate patients."
The deal follows a New York State Department of Health decision in June to allow Irvine, Calif.-based CombiMatrix to provide on a conditional basis array-based miscarriage testing on samples from within the state.
CombiMatrix CEO Mark McDonough said in a statement that adding Manhattan Labs' marketing and distribution support to its own internal sales efforts will be "very beneficial to our growth and prosperity."
In Tuesday morning trade on the Nasdaq, shares of CombiMatrix were up 6 percent at $3.23.